• Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

  • Jun 25 2024
  • Duración: 6 m
  • Podcast

Recce Starts Phase 2 R327 Gel trial for bacterial skin infections Por arte de portada

Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Jonathan Jackson in the Proactive studio after the company obtained Human Research Ethics Committee (HREC) approval to initiate a Phase 2 clinical trial of RECCE® 327 (R327) Gel for acute bacterial skin and skin structure infections (ABSSSI). This trial aims to position R327 Gel as a broad-spectrum treatment for various bacterial skin infections, including complicated skin and soft tissue infections. The trial is an open-label efficacy study and exploratory evaluation designed to assess the systemic bioavailability of single and/or multiple doses of the R327 topical gel applied to ABSSSI, including diabetic foot infections, necrotising fasciitis, and post-operative wound infections. The study seeks to gather critical data on the gel's effectiveness in treating a wide range of ABSSSI conditions. Graham stated that obtaining HREC approval is a significant milestone for the company, highlighting their history of successful approvals and the dedication of their clinical and research teams. The company collaborates with Barwon Health to conduct the trial, enabling access to a diverse patient population and providing valuable insights into the gel's performance across various ABSSSI conditions. Site initiation has begun, with the first patients expected to be dosed in the third quarter of the year. This study builds on previous clinical results from testing R327 on infected burn wounds and diabetic foot infections, under the TGA Special Access Scheme Category A initiative. The centralised study approach aims to address a broad range of unmet medical needs in the topical bacterial infection landscape. ABSSSIs pose a significant challenge to the healthcare system, exacerbated by the rise of antimicrobial resistance, particularly methicillin-resistant Staphylococcus aureus (MRSA). Diabetic patients are at high risk of skin infections and poor outcomes from ABSSSI. The global ABSSSI treatment market was valued at US$7.3 billion in 2018 and is projected to reach US$26 billion by 2032, with a compound annual growth rate of 9.5% from 2019 to 2032. #ProactiveInvestors #ASX #ReccePharmaceuticals, #R327Gel, #ABSSSI, #ClinicalTrial, #Phase2, #HRECApproval, #BacterialInfections, #SkinInfections, #DiabeticFootInfections, #NecrotisingFasciitis, #WoundInfections, #BarwonHealth, #AntimicrobialResistance, #MRSA, #TopicalTreatment, #Healthcare, #PharmaceuticalResearch, #TGA, #InfectionTreatment, #MedicalResearch #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
    Más Menos
activate_primeday_promo_in_buybox_DT
Empresas y Profesiones Economía Finanzas Personales Política y Gobierno
Más Menos

Lo que los oyentes dicen sobre Recce Starts Phase 2 R327 Gel trial for bacterial skin infections

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles